Viking Therapeutics, Inc. (VKTX)
VKTX moved a median of -0.62% 30 minutes after news, and -0.29% by the close. How VKTX actually reacts to news — the realized, point-in-time move the market made, measured across 320 labeled events over the last three years with zero look-ahead.
VKTX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.28% | 41% | 314 |
| 30-min | -0.62% | 43% | 314 |
| 60-min | +0.03% | 50% | 314 |
| to close | -0.29% | 44% | 316 |
| Middle 50% of VKTX reactions | -1.41% to +1.10% |
|---|---|
| Median reaction (30-min) | -0.62% |
| Measured reactions | 320 |
Half of all Viking Therapeutics, Inc. news events land between -1.41% and +1.10% at 30 minutes.
Reaction stats as of 2026-08-31. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How VKTX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 23 | -0.16% | 39% | +0.06% |
| Coverage initiations | 34 | -0.88% | 29% | -0.78% |
| Rating reiterations | 104 | +0.21% | 55% | -0.42% |
| Price-target raises | 15 | +0.14% | 60% | -0.09% |
Last 3 years, pulled 2026-08-31. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how VKTX ranks against every other measured name →
That’s how VKTX usually reacts — get an email when it moves on news →Email me when VKTX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to VKTX's baseline. Nothing else.
Recent VKTX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form S-3ASR Viking Therapeutics, | SEC filing · Form S-3ASR | SEC EDGAR | -4.95% | -1.22% | |
| Form 10-Q Viking Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -4.95% | -1.22% | |
| Form 8-K Viking Therapeutics, For: Jul 29 | SEC filing · Form 8-K | SEC EDGAR | -4.95% | -1.22% | |
| Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | PR Newswire | -4.95% | -1.22% | |
| Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors | Press release | PR Newswire | -0.76% | -3.44% | |
| Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026 | Press release | PR Newswire | -0.76% | -3.44% | |
| Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults | Press release | PR Newswire | +0.06% | +6.29% | |
| Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer | Press release | PR Newswire | -0.63% | +3.66% | |
| Form 8-K Viking Therapeutics, For: May 19 | SEC filing · Form 8-K | SEC EDGAR | -1.66% | +1.15% | |
| Viking Therapeutics to Participate at Upcoming Investor Conferences | Press release | PR Newswire | -0.52% | +5.29% | |
| Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026 | Press release | PR Newswire | -0.83% | -1.32% | |
| Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026 | Press release | PR Newswire | -0.59% | -2.16% | |
| Form 10-Q Viking Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -2.71% | +2.30% | |
| Form 8-K Viking Therapeutics, For: Apr 29 | SEC filing · Form 8-K | SEC EDGAR | -2.71% | +2.30% | |
| Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | PR Newswire | -2.71% | +2.30% | |
| Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026 | Press release | PR Newswire | -0.29% | -4.09% | |
| Viking Therapeutics to Participate at Upcoming Investor Conferences | Press release | PR Newswire | -0.53% | -2.81% | |
| Form ARS Viking Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.00% | +8.41% | |
| Form DEF 14A Viking Therapeutics, For: May 19 | SEC filing · Form DEF | SEC EDGAR | +1.00% | +8.41% | |
| Form DEFA14A Viking Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +1.00% | +8.41% | |
| Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | Press release | PR Newswire | +0.49% | +5.22% | |
| Viking Therapeutics to Participate at Upcoming Investor Conferences | Press release | PR Newswire | -0.84% | +6.77% | |
| Form 10-K Viking Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -3.47% | -10.32% | |
| Form 8-K Viking Therapeutics, For: Feb 11 | SEC filing · Form 8-K | SEC EDGAR | -3.47% | -10.32% | |
| Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update | Press release | PR Newswire | -3.47% | -10.32% | |
| Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026 | Press release | PR Newswire | -1.09% | -7.27% | |
| Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity | Press release | PR Newswire | -3.63% | -1.76% | |
| Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity | Press release | PR Newswire | -0.90% | -2.01% | |
| Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer | Press release | PR Newswire | +0.20% | -0.37% | |
| Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | PR Newswire | +0.38% | +1.32% | |
| Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference | Press release | PR Newswire | +0.91% | +1.60% | |
| Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735 | Press release | PR Newswire | -0.47% | -5.28% | |
| Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025 | Press release | PR Newswire | +1.50% | +3.50% | |
| Viking Therapeutics to Participate at Upcoming Investor Conferences | Press release | PR Newswire | +1.13% | +5.68% | |
| Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2025 | Press release | PR Newswire | +1.09% | +4.43% | |
| Form 10-Q Viking Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.13% | -4.29% | |
| Form 8-K Viking Therapeutics, For: Oct 22 | SEC filing · Form 8-K | SEC EDGAR | -1.13% | -4.29% | |
| Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | PR Newswire | -1.13% | -4.29% | |
| Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity | Press release | PR Newswire | -0.19% | -2.37% | |
| Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025 | Press release | PR Newswire | -0.13% | -2.31% | |
| Viking Therapeutics to Participate at Upcoming Investor Conferences | Press release | PR Newswire | +0.00% | -1.96% | |
| Form 8-K Viking Therapeutics, For: Aug 19 | SEC filing · Form 8-K | SEC EDGAR | -2.27% | — | |
| Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity | Press release | PR Newswire | -2.27% | — | |
| Form 10-Q Viking Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +6.95% | +6.35% | |
| Form 8-K Viking Therapeutics, For: Jul 23 | SEC filing · Form 8-K | SEC EDGAR | +6.95% | +6.35% | |
| Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | PR Newswire | +6.95% | +6.35% | |
| Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025 | Press release | PR Newswire | +1.46% | +0.22% | |
| Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735 | Press release | PR Newswire | -1.49% | -0.07% | |
| Viking Therapeutics to Participate at Upcoming Investor Conferences | Press release | PR Newswire | -1.02% | +2.21% | |
| Form 8-K Viking Therapeutics, For: May 20 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.07% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the VKTX section they belong to.
Where else VKTX is measured.
VKTX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | 323 | -0.14% | 45% |
| Voyager Therapeutics, Inc. (VYGR) | 322 | -0.12% | 41% |
| MATEON THERAPEUTICS (MATN) | 318 | 0.00% | 35% |
| Novartis AG (NVS) | 317 | +0.03% | 51% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Viking Therapeutics, Inc.'s median reaction calculated?
Every labeled VKTX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 320 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 43% of VKTX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-08-31.
Does VKTX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.